text:
quote:Again, your argument is specious just as my crime example points out. Your approach to this argument is basically a universal shut up clause. "Won't fund my desires?.....good, I'll frick up and it will be your fault so that means you are FOR me fricking up". That bull shite could be used for EVERYTHING. That you don't this fact is a window into the shallowness of your thinking.
quote: but I hope you understand how insanely stupid your opinions are too.
quote:Trying too hard
quote: Yea except for the fact that I have data that proves that I'm right.
quote: I could care less where people come out on this because we already won the policy fight
quote:What's more important to you: fewer abortions or making people pay for contraception
quote:In 4 years there will be a Republican in the office for 8 years, that's how this thing goes. The people will be sick of your side in a few years.
quote:Yeah. His "we won" thing amused me. Like that's how elections work. "Election over....end of argument".
quote:Empty place politics.
quote:Like a younger version of DA
quote:I still don't understand what he's arguing against.
quote:With the policy of free contraception as part of insurance coverage the number of unwanted pregnancies goes down
quote:Are you just being stupid because it's cool?
quote:Where is women's birth control free for everyone all of the time?
quote:Where is women's birth control free for everyone all of the time and easy to get to?


text:
Prices and availability are subject to change from the time and date that you print this page.
3/6/2015 11:53:30 PM. For Customer Service, please call
Nod Exclusive
Add our exclusive medium pillow to any of our bedding sets and put an end to "sleepy head" today. Filled with Natural Harmony ™, our exclusive down alternative.

subset: commoncrawl


text:
Player Polished Frame Sunglasses - Smoke Polarized Lens
by Liquid Eyewear
#: 31945
We're sorry, this item is not available in your selected Club.
Check another Club
Perfect for driving, fishing, boating, biking, outdoor recreation and everyday casual wear.
View a video preview of this product.
The Player Polished Frame is an adjustable, hinge-free, hand-polished aluminum providing the ultimate in comfort, fit and durability. The Smoke Polarized Lens design has 14% light transmission, which allows for true color recognition. These high-quality lenses reduce the glare from the sun, making them perfect for the following uses: driving, fishing, boating, biking, outdoor recreation and everyday casual wear. They are not recommended for skydivers or pilots using digital gauges, due to Brewster's angle interference.
Manufacturer Info
Liquid Icon Inc.
Assembled Country
Component Country
Ask & Answer
Warranty Information
This product is covered by the Sam's Club Member Satisfaction Guarantee.There is no additional information available for this item.


text:
By Barbara Kessler
Green Right Now
Winter is not when we typically think strategically about trees. We may notice the glittering displays of icicles draped from their branches as we re-stack the firewood pile and shovel the front walk. But tree maintenance? It shifts to the bottom of our checklist.
And yet, the winter months are an excellent time to train an eye on our arboriculture — to check for cracking or peeling bark, identify broken branches and address damage from ice and snow storms.
Let's consider first those broken branches. There are likely to be many this winter as the nation endures repeated onslaughts of arctic winds and weather.
The first thing to do when seeing a tree in trouble, says Arbor Day Foundation arborist Robert Smith, is to carefully assess the damage, and be realistic and safe in how you deal with the problem.
Smith often advises homeowners to take a binoculars out and examine large trees for immediate weather damage, as well as existing problems that may not have been evident when the tree was in full foliage. But he stresses that a tree owner should stay grounded.
"If you're going out and inspecting the tree, the first consideration always is safety," Smith said. "If it's a young tree planted in the last couple years that's out on your property and there's some damage and there's work that could be done from the ground… you could remove cracked or down branches."
If you find yourself heading to the garage for a ladder, however, stop yourself, says Smith. Taller trees require the expert attendance of a certified arborist, who will have the appropriate equipment.
Not only do most homeowners lack the proper saws to make the necessary clean cut needed so the tree seal off the wound, they probably have no training in safe arbor care, and many have been seriously injured or killed in falls, says Smith. (Those saws, btw, are available for sale at some hardware store, but always at specialized tree care retailers like Sherrill Tree for those who have smaller trees to manage.)
Even though it's winter, don't hesitate to call an arborist, says Smith, because a tree expert can actually get a lot accomplished in these chilly months when the trees are in their latent stage.
Trees can be successfully pruned in the winter, and may even do better being pruned in advance of the growing season.
Most importantly, a certified arborist can best advise you about how to proceed with a tree that's been damaged. Often there's a way to save the tree, and that's not just tree-hugger talk.
Smith remembers an early season blizzard that slammed Lincoln, Nebraska, where Arbor Day is based, 12 years ago. It began with a sudden freezing rain, hitting trees that were still green and growing. Within 24 hours, they were coated in ice and weighted with snow. Many of the trees must have looked beyond recovery, to the unstudied eye, he said. But more than a decade later, Smith can see many that survived that early winter blast. They're the ones that were properly trimmed and given a chance to continue growing.
So don't give up on 20 or 30 years of natural shade unless you're certain the tree has been fatally compromised. A key to helping the tree recover is that clean cut. "Trees don't heal, they seal. They actually wall off or compartmentalize injuries. They don't heal like you and I do, they don't heal, they actually wall off injuries," Smith said.
Arbor Day offers specific guidance on cutting trees limbs. The tree advocacy non-profit also issues guides on assessing damaged trees, such as its step-by-step Can They Trees Be Saved guide (see image, right), to help tree owners determine how to proceed with an impaired tree. This guide acknowledges that sometimes trees are injured beyond help, and offers depictions of what that sort of damage looks like.
The group also issues tips on what Smith calls "tree triage" or first aid for trees. This guide urges homeowners to approach the problem with caution, gives specifics about pruning branches and argues for a conservative approach to save trees when possible. It advises:
- Removing the jagged remains of smaller sized broken limbs is one common repair that property owners can make after a storm. If done properly, it will minimize the risk of decay agents entering the wound.
- Smaller branches should be pruned at the point where they join larger ones.
- Large branches that are broken should be cut back to the trunk or a main limb by an arborist. Cut first a short distance out from where the branch meets the tree; then closer in. (See details at Arbor Day's webpage on pruning. )
Some other dos and don'ts from Smith and the Arbor Day Foundation:
- Don't let a passing work crew "take out" your damaged tree before you can have it professionally assessed. The tree might be salvageable, but the people soliciting your business are likely to be more interested in earning some quick cash than the long term viability of your landscape.
- Recognize that you don't have to make an immediate decision about whether a tree should be removed. "There are times when people can come in and prune a tree that's been severely damaged and then evaluate the health and condition of that tree over a period of years, then with an arborist make a decision whether or not it should remain in the landscape," Smith said.
- Water trees in winter? Sure. Even better, deep water them, around the fall line away from the trunk, in late autumn, says Smith. That's when you also should place mulch around the base, though not up against the trunk, which can invite pests. Mulch keeps soil moist and warm in the cold season, just as it helps during the summer to moderate the soil temperature. If winter is dry and windy where you are, water trees just as you might in warmer weather. You can also shield trees, especially new ones, from winter winds by surrounding them with a mini-fence of chicken wire, set out from the trunk, and covered with burlap, as Smith does.
- But when it comes to extra pruning, just say no. "Topping" a tree by cutting its canopy, can be harmful to decorative trees or any specimen. "Topping trees is always a bad idea," says Smith. It never helps, and often hurts the health of the tree. Even those crape myrtles in the South are damaged by the winter shearing that many undergo. In the business, Smith said, this popular but ill-advised practice has been nicknamed "Crape Murder". Read more about shearing back on shearings at the website Plant Amnesty.
So tend to those trees in winter — on calm and sunny days, and you may be rewarded with a bounty of spring foliage.
Copyright © 2010 Green Right Now | Distributed by GRN Network


text:
quote:Why did Tommy have to lose?
quote: because he is a war criminal
quote:because he is a war criminal/deserter
quote:He let Brendan win.
quote:This was almost a negligible point in the plot
quote:what if he had not broken his arm? Would he just let Brendan knock him out?
quote:he was going to be arrested as soon as the fight was over. they would not have let him keep the money.
quote:they would not have let him keep the money.
quote:Such a good movie.
quote:He let Brendan win. At least that was what I got out of the ending.
quote:Tommy lost due to poor writing
quote:Tommy destroyed the competition too easily for him to go out like that. They should have matched him with Koba to show he slowed down a little bit.
quote: Funny how Brendan turns into the submissive juggernaut and Tommy is nothing but a heavy handed, hit it and quit, one and done brawler...


text:
Start learning with our library of video tutorials taught by experts. Get started
Reviews the history of version control and demonstrates its fundamental concepts: check-in/checkout, forking, merging, commits, and distribution.
"Through your company I am experiencing the real joy of education. It is incredibly motivating to see the passion of the teachers in each course." —Saif R.
more from our members »


text:
Food allergies have been on the rise in recent years. Studies suggest that up to 1 in 13 children are affected by a food allergy. Egg and cow's milk are the most common food allergies for infants and toddlers. Fortunately, most children will lose a milk or egg allergy by the time they enter school. Peanut and tree nut allergies are also becoming more common. Unfortunately, only 10-20% of children will ever outgrow a nut allergy.
Currently there is no cure for food allergies. Instead, doctors rely on an accurate diagnosis, avoiding food triggers, and being prepared in the event of a severe reaction. Making the situation more challenging, nearly half of children with a food allergy may be at risk for a potentially life-threatening reaction called anaphylaxis.
Symptoms of anaphylaxis may include:
- hives or itchy welts
- swelling
- vomiting or diarrhea
- difficulty breathing (cough, wheeze or shortness of breath)
- dizziness or passing out
During a severe food allergy reaction, epinephrine ("adrenaline") can be a life-saving medication. Epinephrine is typically injected into a thigh muscle with an "auto-injector" device like EpiPen® or Auvi-Q™. Oral antihistamines like Benadryl, Allegra, or Zyrtec can help with some anaphylaxis symptoms, but are not considered life-saving treatment.
Emergency Epinephrine in Schools
Until recently, only certain students in Washington State could receive a life-saving epinephrine injection while at school. They needed to be diagnosed with a food allergy and already have an epinephrine injector in the health room. However, some students may not have an injector at school, or they have their first serious allergic reaction while at school. In that case, the school could only call 911 and hope they arrived in time to save a life.
In January 2013...


text:
Design: RC287
India Flowers Round Sticker Decals
Personalized Sticker Circle 3" White
Made to Order - 1 business day processing+shipping
Sale Price: $0.25 each
Was $0.29,
You save 13%
Minimum Order Quantity: 12
Personalized Sticker Circle 4" White
Made to Order - 1 business day processing+shipping
Sale Price: $0.35 each
Was $0.39,
You save 10%
Minimum Order Quantity: 12
Personalize an India design flower!
These India Flowers Round Sticker Decals allows you to customize your sticker. Our India Floral Sticker Decals are printed on white sticker material that comes in 3 or 4 inch sizes.
Not for use on windows.
Please allow ample time for delivery. Our ship date for this product is noted in your shopping cart. Many items are shipped separately, so please allow extra time for these items to arrive. Shipping charges are based on the value of the merchandise and not the number of shipments. For additional shipping information, contact our Customer Service Department at (email@example.com or 1-800-314-8794).
Detailed shipping information
Detailed shipping information
Recommended Items
Questions & Answers
Recommended Products
People who viewed "India Flowers Round Sticker Decals" also viewed


text:
New day. New Daily Deals. Get them before they are gone!
Can't find what you're looking for? Shop all ink and toner cartridges by brand
New Customer ? Start Here.
New day. New Daily Deals. Get them before they are gone!
Call Customer Support 1 (800) STAPLES
Shredders offer effective data protection by allowing you to eliminate unnecessary hard copies. Quickly and easily eliminate sensitive printouts with systems that use high-powered cutting blades in strip or crosscut configurations. Modern shredders can remove staples and clips for easy recycling.
Protect Sensitive Data
Shredders quickly eliminate sensitive information by allowing you to render printed pages illegible in moments. This can help keep important financial details or related business documentation from falling into the wrong hands. Many industry and government regulations require shredding for compliance with data protection laws or statutes.
Quick Operation
Advanced shredders can handle document destruction at rates of 8 feet per minute or greater. This fast operation can save you labor costs associated with shredding and help increase overall efficiency. For even quicker operation, check out auto-feed mechanisms, standalone bags, and other shredder accessories.
Jam-Proof Designs
Many shredders on the market today feature jam-proof designs that can easily cut through staples or paper clips without the cutting mechanism stopping. This reduces downtime by ensuring that your shredder is constantly running when you need it, and the jam-proof design also makes quick work of bunched or crumpled paper. Many jam-proof systems allow easy access to trays that store clipped staples and other metal materials for easy recycling.
Safe Operation
Modern shredders offer a bevy of features that make them much safer to operate than their earlier counterparts. A touch-sensitive operation shuts down cutting mechanisms when it detects fingers too close to shredder feed areas, helping to keep hands safe. Many systems also include auto-shutoff mechanisms that identify when someone is attempting to pull a piece of loose clothing or other snagged item from the machine.
This Web site is intended for use by US residents only. See International Sites. See our delivery policy for full details. Copyright 1998-2014, Staples, Inc., All Rights Reserved.


text:
Drug Combination Cuts Risk of Advanced Colon Polyps Results from a phase III clinical trial indicate that low doses of two chemopreventive agents, an anti-inflammatory and an experimental compound, are highly effective at preventing the recurrence of the lesions that are often precursors to colorectal cancer.
Mutant Gene Linked to Aggressive Leukemia Researchers have identified a common genetic change in Philadelphia chromosome (BCR-ABL1)-positive acute lymphoblastic leukemia (ALL), an aggressive leukemia that carries a poor prognosis. The change alters the gene IKZF1, which produces the protein Ikaros, and appears to be an important lesion in this ALL subtype, the researchers reported online in the April 13 Nature. Ikaros plays a key role in regulating the normal development of lymphocytes. The IKZF1 gene alterations were detected as part of an ongoing effort to identify genetic abnormalities in ALL. Dr. James Downing of St. Jude Children's Research Hospital and his colleagues analyzed DNA copy number changes in 304 ALL cases, including 21 children and 22 adults with BCR-ABL1-positive disease. Read more
Drug Combination Cuts Risk of Advanced Colon Polyps Results from a phase III clinical trial indicate that low doses of two chemopreventive agents, an anti-inflammatory and an experimental compound, are highly effective at preventing the recurrence of the lesions that are often precursors to colorectal cancer. Trial results presented yesterday at the American Association for Cancer Research (AACR) annual meeting in San Diego, CA, showed that, compared with participants in the placebo arm, those treated with a combination of the investigational compound difluoromethylornithine (DFMO) and the anti-inflammatory agent sulindac had their risk of colon polyp recurrence reduced by 70 percent. More important, the results showed that the treatment was most effective in preventing the recurrence of the highest-risk polyps, advanced adenomas, demonstrating a 92 percent reduction. "This is the most positive trial in chemoprevention in the last 20 years," says the trial's lead investigator Dr. Frank L. Meyskens from the Chao Family Comprehensive Cancer Center at the University of California, Irvine. "It should raise great hope that we'll be able to use chemoprevention in appropriate at-risk groups." The trial was stopped early, following a recommendation by its Data Safety Monitoring Board, because the trial's primary goals had been met. Although 375 patients were randomly assigned to the placebo or intervention arms, the final analysis was based on data from 267 patients for whom the most complete information was available. All patients in the trial had previously had colorectal adenomas (3 mm or larger) removed, and the study treatment lasted for 36 months. "This is a phase III study that demonstrates a lot of potential for this drug combination to decrease cancer risk," says Dr. Eva Szabo from NCI's Division of Cancer Prevention. Data on cancer incidence are not yet available from the trial. "However," Dr. Szabo continues, "we understand the biology of polyp progression to colon cancer quite well." Given the decrease in adenoma recurrence seen in the study, there is a very strong likelihood of a true cancer prevention effect, she notes. Originally developed by a French pharmaceutical company, DFMO inhibits a cell's synthesis of molecules called polyamines by blocking the function of an enzyme known as ornithine decarboxylase. Based on data from laboratory and animal model studies, explains Dr. Meyskens - who, along with Dr. Eugene Gerner from the Arizona Cancer Center, has been studying DFMO since the early 1980s - the combination of DFMO and sulindac makes sense for cancer prevention. "They affect two different pathways, both of which drive proliferation," he says. Sulindac was an early member of the class of drugs known as nonsteroidal anti-inflammatory drugs, or NSAIDs. That same class also includes celecoxib (Celebrex), a COX-2 inhibitor that has had mixed results in other large adenoma recurrence prevention trials. It decreased adenoma recurrence but also increased the risk of serious cardiac events. However, Dr. Meyskens cautions, "I don't think our study has gone on long enough to know whether sulindac has cardiovascular effects." There was an increase in cardio-vascular events, but it was not statistically significant. The trial was launched only after two smaller "dose de-escalation" studies were done to identify the lowest effective dose of DFMO that could provide a clinical benefit. The dose used in this prevention trial is one-fiftieth of the dose used in the earlier treatment trials. Based on earlier studies, some concerns do exist about DFMO-related toxicities, namely hearing loss. More patients in the DFMO/sulindac arm did experience minor reductions in hearing, as measured on audiograms. Participants who experienced hearing loss, mostly older participants, generally weren't aware of it. "Across the entire group, the difference in hearing loss between treatment and placebo was approximately 2 decibels," he says. "That's [the sound of] rubbing your fingers together." Dr. Meyskens' group is working with NCI to design larger phase III trials, including one in patients who have been treated for low-grade colorectal cancer. Currently, DFMO is not manufactured by any pharmaceutical company, so the team is also searching for industry partners to continue moving it through additional clinical trials and, they hope, regulatory approval. "We hope these data will generate a lot of interest," Dr. Meyskens says. —Carmen Phillips |
Mutant Gene Linked to Aggressive Leukemia Researchers have identified a common genetic change in Philadelphia chromosome (BCR-ABL1)-positive acute lymphoblastic leukemia (ALL), an aggressive leukemia that carries a poor prognosis. The change alters the gene IKZF1, which produces the protein Ikaros, and appears to be an important lesion in this ALL subtype, the researchers reported online in the April 13 Nature. Ikaros plays a key role in regulating the normal development of lymphocytes. The IKZF1 gene alterations were detected as part of an ongoing effort to identify genetic abnormalities in ALL. Dr. James Downing of St. Jude Children's Research Hospital and his colleagues analyzed DNA copy number changes in 304 ALL cases, including 21 children and 22 adults with BCR-ABL1-positive disease.
The researchers also analyzed 23 cases of chronic myelogenous leukemia (CML), which also involves BCR-ABL1 and is commonly treated with imatinib (Gleevec). Left untreated, CML may progress from an indolent stage to an acute leukemia known as blast crisis. The researchers observed Ikaros deletions at the progression of CML to lymphoid blast crisis, suggesting that Ikaros mutations help determine the behavior of BCR-ABL1 leukemia. "BCR-ABL1 is the hallmark of CML, but this disease is complex," noted lead author Dr. Charles Mullighan of St. Jude. "Our results show that other genetic lesions are involved in the progression of CML to blast crisis, and in de novo BCR-ABL1 ALL. These additional lesions may be critical in the response of these diseases to treatment." Chromosome Region Linked to Lung Cancer A region of chromosome 15 may contain genetic risk factors for lung cancer, three research teams reported online this month in Nature and Nature Genetics. The results are from the first genome-wide association studies to attempt to identify the genetic component of a disease that is closely associated with a strong environmental cause. Yet researchers have long known that genetic factors play a role in lung cancer risk, and recent studies have implicated this region in the disease. More work is needed to identify which DNA sequences in the region are responsible for the increased risk observed in the studies. The leading suspects are three genes that produce proteins on the cell surface that bind to nicotine, triggering a cascade of cellular changes, including some related to cancer. These proteins may contribute to cancer in the absence of exposure to nicotine. The studies were led by Dr. Kari Stefansson of deCODE Genetics in Iceland; Dr. Paul Brennan of the International Agency for Research on Cancer in Lyon, France; and Dr. Christopher Amos of the University of Texas M.D. Anderson Cancer Center. The results provide strong evidence for a link between DNA variants on chromosome 15 and lung cancer, but the studies differ on whether the connection is direct or mediated through smoking behavior, according to an accompanying commentary in Nature. Even larger studies with detailed information about smoking patterns and addictive behavior will be needed to discern whether "these discoveries relate to the risk of smoking, the risk of lung cancer, or the risk of both," write Drs. Stephen Chanock of NCI's Division of Cancer Epidemiology and Genetics and David Hunter of the Harvard School of Public Health. IV Iron Effective in Treating Chemotherapy-Induced Anemia Two studies in the April 1 Journal of Clinical Oncology (JCO) found that intravenous (IV) iron significantly improves hemoglobin levels in patients taking erythropoietin-stimulating agents (ESAs) for chemotherapy-induced anemia compared with ESAs alone or ESAs plus oral iron. Anemia occurs in up to 75 percent of cancer patients who undergo chemotherapy or radiation treatment in clinical trials, and ESA therapy has been found to correct the blood condition in only 50 to 70 percent of patients. In the first JCO study, 86 percent of patients receiving the ESA darbepoetin alpha (Aranesp) plus IV iron achieved either a hemoglobin level of at least 12 g/dL or an increase of at least 2 g/dL over their baseline hemoglobin level, compared with 73 percent of patients who received the ESA alone or ESAs with oral iron. Patients receiving IV iron responded more quickly to ESA therapy, achieving target hemoglobin levels in a median of 50 days compared with 64 days for patients not receiving IV iron. In the second study, 76.7 percent of patients receiving darbepoetin alpha with IV iron achieved target hemoglobin levels, compared with 61.8 percent of patients receiving ESA therapy alone. Last month, the U.S. Food and Drug Administration's Oncologic Drug Advisory Committee recommended substantially limiting the use of ESAs to treat anemia in cancer patients after clinical trials showed an increased mortality risk in patients using ESAs to achieve hemoglobin levels of 12 g/dL or higher. However, in an editorial accompanying the JCO articles, Dr. Michael Auerbach of Georgetown University writes: "These two studies add unique and useful information to a rapidly growing body of data supporting the routine use of IV iron as an adjunct to ESA therapy in appropriately selected oncology patients." |
At AACR, New Science and an Important Dialogue Each annual meeting of the large U.S. and international cancer research organizations has its own unique aspects, its own atmosphere. Over the past several years, the American Association of Cancer Research (AACR) annual meeting has begun to feature more clinical and translational research, while maintaining its focus on the basic sciences. It is this "bench to bedside and back" approach that makes it such an important meeting. At this year's meeting, some conference rooms have been overflowing with attendees wanting to hear pre-eminent researchers discuss their latest thinking on topics such as making rational decisions about combination therapies with targeted agents. Meanwhile, many press conferences have featured young investigators who, often for the first time, are being given an opportunity to present exciting new data from important research projects they have led. This year's meeting has been notable for other reasons. In particular, data from some early- and late-phase clinical trials have generated tremendous optimism. Dr. Daniel Von Hoff presented exciting data from a phase I, first-in-man study involving an experimental Hedgehog pathway inhibitor. The data suggest that this agent has the potential to treat the rare patient who develops metastatic basal cell carcinoma. This trial is also a tribute to the tremendous basic research that elucidated this signaling pathway's potentially important role in cancer. On a personal level, this year's meeting was also noteworthy because I had the opportunity to participate in what outgoing AACR President Dr. William Hait described as an "experiment:" a session in which, after a brief presentation, a number of attendees asked me questions about some of the most prominent issues facing NCI and the broader cancer community. In particular, it was clear that there is tremendous concern about ensuring that young investigators get the support and opportunities they need to become successful cancer researchers. This is clearly a very important issue, and it is among my top priorities. Indeed, every time I testify before congressional committees or meet with legislators and their staff, I underscore the impact five years of flat budgets have had on the pipeline of young investigators and that despite the high priority NCI places on training and supporting young investigators, there are limits to what we can do with our available resources. There were questions about investigator-initiated versus program-directed grants and team science as well. In my reply, I emphasized NCI's priority to vigorously protect the unsolicited grant portfolio during budgetary stresses - and these grants are anticipated to grow with new resources from future budgets. Nonetheless, our individual investigator grants have eroded not only in their success rates but also in their size. Current awards are inadequate to support the cost of today's science. In addition, I was able to mention changes in other areas of our research portfolio, especially in our larger programs, to reflect the changing research environment. For example, as a result of recommendations from the Translational Research Working Group, adjustments are being made to integrate the Specialized Programs of Research Excellence (SPORE) program into NCI's broader translational research program, enhance peer review, and more closely align individual SPORE funding to its priority score. In discussing the ways in which NCI is improving the clinical trials process, I also stressed how important it is for the institute to create opportunities for connectivity between academia and industry and also between research progress and community cancer care. On the clinical trials front, for example, the Cancer Biomedical Informatics Grid will be critical for connecting researchers and providing new tools and resources that have the potential to improve the efficiency of the clinical trials process. As this dialogue and the AACR annual meeting have shown, the dedication of those in the cancer community to reduce the cancer burden has grown stronger despite the challenges we currently face.Dr. John E. Niederhuber |
AACR Annual Meeting Coverage APC 5-Year Results: Adenoma Recurrence Reduced, Cardiac Risks Clearer The 5-year results of the Adenoma Prevention with Celecoxib (APC) trial indicate that 2 years after daily use of celecoxib (Celebrex) has ended, there continues to be a modest reduction in the recurrence of colorectal polyps. Initially presented at the 2006 AACR annual meeting, the trial's results showed that compared with placebo, adenoma recurrence and advanced adenoma recurrence were significantly reduced in participants who took celecoxib daily for 3 years. Participants, all of whom had previously had lesions removed, had significantly fewer total adenomas and advanced adenomas at 3 years. Speaking yesterday at the 2008 AACR annual meeting in San Diego, CA, the trial's lead investigator, Dr. Monica Bertagnolli, reported that although the effect diminished after the drug was discontinued, a treatment benefit was still present at 5 years. Celecoxib use, however, was associated with an increased risk of serious side effects, including heart attacks and strokes. The safety analysis suggests that these serious adverse events were greatest in participants with pre-existing cardiovascular risk factors. Overall, compared with participants in the placebo arm, advanced adenoma risk was reduced by 41 percent among patients taking the 400 mg/day dose and 26 percent among patients taking the 800 mg/day dose. Cardiovascular events were far more likely among participants who had at least two pre-existing cardiovascular risk factors (e.g., high blood pressure, diabetes, age of more than 65 years) at study entry: 5.9 percent of participants in the placebo arm, compared with 8.2 percent in the 400 mg/day arm and 11.2 percent in the 800 mg/day arm, reported a cardiovascular adverse event. By contrast, for APC participants who had no cardiovascular risk factors at study entry, the rates of cardiovascular adverse events were 0.9 percent, 3.9 percent, and 1.9 percent, respectively. The results, said Dr. Bertagnolli, of Brigham and Women's Hospital demonstrate that COX-2 inhibitors "are risky for some patients." But, she continued: "Our study also shows that for patients without major cardiovascular risk factors, celecoxib at low doses protects against high-risk lesions that can lead to colon cancer." These results come on the heels of a more extensive, NCI-funded cross-study safety analysis of six placebo-controlled studies involving celecoxib. These data were presented in late March at the annual meeting of the American College of Cardiology. That analysis showed a threefold increased risk of cardiovascular events in patients given the highest celecoxib dose, but also showed that risk was significantly higher among study participants with underlying cardiovascular risk factors. Finding and Studying Pancreatic Cancer Stem Cells A refined strategy for isolating cancer stem cells in pancreatic tumors and preliminary evidence that these rare cells may influence patient survival were presented at the 2008 AACR annual meeting. The results are from a series of studies at the Johns Hopkins Kimmel Cancer Center aimed at understanding the potential role of pancreatic cancer stem cells in this deadly disease. The cancer stem cell hypothesis holds that many cancers are initiated and driven by these elusive cells, which are capable of perpetuating themselves while giving rise to tumors. In 2003, lead investigator Dr. William Matsui and his colleagues identified cancer stem cells in patients with multiple myeloma, a cancer of the bone marrow. Building on this work, the researchers have now developed a strategy for isolating potential pancreatic cancer stem cells that integrates markers from different studies. The strategy combines the surface proteins CD44 and CD24 (used last year by a University of Michigan team to identify pancreatic cancer stem cells) with the enzyme aldehyde dehydrogenase, which was a marker in the Hopkins multiple myeloma studies. Using all three markers together yielded a stem cell population that was 2 to 10 times more concentrated than using either type of marker alone, Dr. Zeshaan Rasheed from Johns Hopkins reported at AACR. In further studies, the researchers found that patients whose tumors lack the cancer stem cell markers live a few months longer than other patients. This difference may be meaningful in a disease in which most patients die within a year of diagnosis. "We're starting to get some inkling that these cells are clinically relevant in this disease," noted Dr. Matsui. His team has been investigating whether cancer stem cells contribute to metastasis, and a publication describing all of the studies is planned. Synthetic Vitamin D Shows Anti-cancer Effect and No Toxicity in Mice and Rats Researchers at Rutgers University have developed a form of active vitamin D called Gemini 0097 that dramatically reduced the growth of both ER-positive and ER-negative breast cancer cells and showed no toxicity in rats and mice. Dr. Nanjoo Suh presented the results of her team's study at AACR yesterday. The active form of vitamin D is a hormone synthesized by the skin, liver, and kidneys from dietary precursors. Epidemiological studies have shown that people deficient in active vitamin D have a higher risk of colorectal, breast, prostate, and other cancers. Clinical studies using vitamin D supplements to prevent cancer have produced mixed results, in part because of the fact that high doses of vitamin D in its active form can cause an imbalance in other electrolytes, including toxic levels of calcium in the blood. For this reason, researchers have been testing analogs of vitamin D, chemically modified forms of the vitamin that have a slightly different molecular structure. The Rutgers team tested 60 new analogs of active vitamin D against a placebo in rats that had been exposed to mammary carcinogens. One of the analogs, Gemini 0097, was superior for preventing tumor development, cutting ER-positive breast cancer growth by 60 percent. In a mouse model of ER-negative breast cancer, Gemini 0097 reduced tumor development by 50 percent. Blood calcium levels remained normal in mice and rats that received the analog treatment. "Our analog has a side-chain that makes the molecule much bulkier than naturally occurring vitamin D, such that the binding of the molecule to its receptor is only 40 percent, but somehow the activity is better," explained Dr. Suh. She speculated that this superior activity may be caused by alternative recruitment of co-factors to the vitamin D receptor. Dr. Suh noted that more data from animal studies are needed before Gemini 0097 is tested in humans. Reduction in Breast Cancer Incidence Differs by Race Recent studies have reported that after rising for two decades, the breast cancer incidence rate in the United States dropped sharply between 2002 and 2003 and continued to decline in 2004. However, new research presented April 15 at the 2008 AACR annual meeting shows that this decline was not equally distributed across racial groups. Investigators from the University of Chicago used data from 17 cancer registries of the Surveillance, Epidemiology, and End Results program to calculate changes in incidence for invasive and in situ female breast cancer between 2000 and 2004 by race and tumor stage in women aged 50 to 69. The incidence rate of in situ cancer remained stable in most groups of women. However, the investigators found that while rates of invasive breast cancer decreased significantly for Caucasian women by the end of 2003, the incidence rates did not change significantly for African American, American Indian/Alaskan Native, or Asian American/Pacific Islander women. "This racial disparity is consistent with the hypothesis that discontinuation of hormone replacement therapy (HRT) may have caused the dramatic reduction," stated the authors in their abstract presented at AACR. "We suspect that the widespread discontinuation of menopausal hormone use had a greater effect on Caucasians," said Dr. Dezheng Huo in a press release from the University of Chicago. African Americans are less likely to develop breast cancers that are receptive to estrogen, Dr. Huo explained, so they were harmed less by taking hormones and benefited less by discontinuing them. In addition, African Americans had "a similar magnitude of reduction in hormone therapy," said Dr. Huo, "yet it did not lead to any benefit, suggesting that genetic variations in estrogen and progesterone metabolism play a role." |
Improving Unrelated Hematopoietic Stem Cell Transplants The field of hematopoietic stem cell transplantation (HSCT), in which cancer patients and people with certain other diseases receive transplanted blood-producing stem cells to restore their blood and immune systems after treatment, has seen several exciting developments in recent years. The discovery of non-bone marrow stem cell sources, including peripheral blood and fetal cord blood, has increased the supply of unrelated-donor (allogeneic) stem cells available for patients. And lower-toxicity treatment regimens - mini-transplants that merely suppress a patient's immune system before the transplant, rather than eliminate all blood-forming cells - have allowed patients who would previously have been ineligible for the procedure to receive it, including older adults and those who have comorbid conditions. Hoping to build on these previous successes, researchers in the NCI Center for Cancer Research's Experimental Transplantation and Immunology Branch (ETIB) have launched a new initiative to explore how to optimize HSCT to maximize the benefits of the procedure while minimizing its risks. "Our goal is to overcome the four primary barriers to HSCT: rejection, graft-versus-host-disease, tumor relapse, and lack of immune reconstitution," explains ETIB Chief Dr. Ronald Gress. The factor that influences each of these barriers most is antigen mismatching between an HSCT donor and recipient. Human leukocyte antigens are important proteins for determining this match, but other, lesser-known cell-surface proteins also play a role. When a match is imperfect, transplanted cells can react against the recipient in what is called graft-versus-host disease, causing damage throughout the body and possible death. However, mismatched transplanted immune cells are also capable of doing what the recipient's immune system could not: recognizing and killing cancer cells. This reaction is called graft-versus-tumor effect, and with some forms of cancer, it not only restores the immune system, but actually cures the disease. A part of this new ETIB initiative is a pilot study to look at HSCT from fully matched unrelated allogeneic donors and its potential to cure. Senior Investigator Dr. Michael Bishop and colleagues will compare two treatments that have been used in preventing graft-versus-host disease after mini-transplants: a combination of tacrolimus, methotrexate, and sirolimus; and a combination of cyclosporine and alemtuzumab. The primary objective of the pilot study is to look at the safety of each regimen, as well as how each affects the speed of engraftment and immune reconstitution after the transplant. A secondary objective is to examine immune reconstitution using a technique known as CDR3 spectratyping, where polymerase chain reaction and gel electrophoresis are used to analyze the diversity and population of T cells against antigens. "We're taking a personalized approach to transplantation," says Dr. Bishop. In the early days, he explains, all patients received the same transplant preparation drug doses, regardless of what treatments they had previously. "This is like using a really big hammer for every size nail," he says. But how intact a patient's immune system is varies according to how much chemotherapy the person has received. Patients who have very weak immune systems do not need the same doses of immune-suppressing drugs as someone whose immune system is comparatively strong. T-cell number revealed by CDR3 spectratyping can guide this dosing decision, determining the competence of the rejection response in these patients. "We can use this personalized preparation, which was developed with Dr. Dan Fowler in ETIB, to lower the immune systems only as much as is needed, so that each patient is on an equal playing field and each person has an equal chance that their graft will be successful, while sparing patients unnecessary toxicity," explains Dr. Bishop. The spectratyping can be used afterward to show how well each patient's immune system recovers. Dr. Bishop's pilot study marks the first time that allogeneic transplants from unrelated donors are being studied by NCI at the NIH Clinical Research Center (CRC), and it will establish a platform in ETIB for future studies, including the use of cytokine-defined T-cell subsets to reduce transplant rejection and graft-versus-host disease, ways to increase function of the thymus gland to improve immune reconstitution, and new strategies to prevent and treat disease relapse. "Unrelated transplants are being performed all over the country, but the ability to engraft cells from an unrelated donor while minimizing chemotherapy and maximizing graft-versus-tumor effect is not being tested anywhere else in this individualized way," says Dr. Gress, who notes that several other institutes at NIH have a stake in the HSCT research being performed. —Brittany Moya del Pino |
Herbal Therapy for Brain Cancer Name of the Trial Principal Investigator Why This Trial Is Important Resin from the Boswellia serrata tree (frankincense) has been shown in animal and human studies to reduce inflammation, which is a primary cause of brain edema. Additionally, laboratory studies suggest that B. serrata resin may also cause human brain cancer cells to undergo programmed cell death (apoptosis). In this trial, patients will be randomly assigned to take an herbal preparation of B. serrata orally four times a day in conjunction with standard treatment for six months or to take standard treatment alone for six months. All patients are advised to eat a low-fat healthy diet. Diets rich in red meat contain a substance called arachidonic acid, and chemicals in fat can be converted to arachidonic acid. Arachidonic acid is converted in the brain to signaling molecules called eicosanoids that may promote inflammation and tumor growth. Doctors want to see if B. serrata can help reduce brain edema, tumor growth, and levels of 5-lipoxygenase, an enzyme that helps convert arachidonic acid to eicosanoids, in these patients when combined with standard treatment. "Some small studies have suggested that frankincense extract may help limit brain edema and even have an anti-tumor effect," said Dr. Stevens. "We hope that use of this herbal preparation in conjunction with a healthy diet will help improve patient outcomes and act in a complementary fashion with standard treatments for high-grade gliomas." For More Information An archive of "Featured Clinical Trial" columns is available at http://www.cancer.gov/clinicaltrials/ft-all-featured-trials. |
AMA Honors NCI's Linehan Dr. Linehan received the award at the AMA's national advocacy conference on April 1 in recognition for his leadership and contributions to kidney cancer research. Dr. Linehan and his colleagues have discovered multiple genes linked to kidney cancer and established a comprehensive kidney cancer program at NCI to study families with the disease. Hoover Receives AACR Award Monograph on Middle East Palliative Care Available NCI Cancer Bulletin Wins Award |
Following are newly released NCI research funding opportunities: Cancer Education Grants Program Application Receipt Dates: Non-AIDS Applications (new, renewal, resubmission, or revision): This is a renewal of PAR-06-540 and will use the R25 award mechanism. For more information see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3865. Inquiries: Dr. Lester S. Gorelic - firstname.lastname@example.com. Symptom Interactions in Cancer and Immune Disorders Application Receipt Dates: Non-AIDS Applications (new): June 5 and Oct. 5, 2008; Feb. 5, June 5, and Oct. 5, 2009; Feb. 5, June 5, and Oct. 5, 2010; Feb. 5, 2011. This is a renewal of PA-07-009 and will use the R01 award mechanism. For more information see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3866. Inquiries: Dr. Ann M. O'Mara - firstname.lastname@example.com. Enhancing Tumoricidal Activity of Natural Killer Cells by Dietary Components for Cancer Prevention Application Receipt Dates: Non-AIDS Applications (new): June 5 and Oct. 5, 2008; Feb. 5, June 5, and Oct. 5, 2009; Feb. 5, June 5, and Oct. 5, 2010; Feb. 5, 2011. This funding opportunity will use the R01 award mechanism. For more information see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3867. Inquiries: Dr. Young S. Kim - email@example.com. Correlative Studies with Specimens from Multisite Trials Application Receipt Dates: Non-AIDS Applications (new): June 5 and Oct. 5, 2008; Feb. 5, June 5, and Oct. 5, 2009; Feb. 5, June 5, and Oct. 5, 2010; Feb. 5, June 5, and Oct. 5, 2011; Feb. 5, 2012. This is a renewal of PA-07-177 and will use the R01 award mechanism. For more information see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3868. Inquiries: Dr. Heng Xie - email@example.com. Symptom Interactions in Cancer and Immune Disorders Application Receipt Dates: Non-AIDS Applications (new): June 16 and Oct. 16, 2008; Feb. 16, June 16, and Oct. 16, 2009; Feb. 16, June 16, and Oct. 16, 2010; Feb. 16, 2011. This is a renewal of PA-07-009 and will use the R21 award mechanism. For more information see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3866. Inquiries: Dr. Ann M. O'Mara - email@example.com. Enhancing Tumoricidal Activity of Natural Killer Cells by Dietary Components for Cancer Prevention Application Receipt Dates: Non-AIDS Applications (new): June 16 and Oct. 16, 2008; Feb. 16, June 16, and Oct. 16, 2009; Feb. 16, June 16, and Oct. 16, 2010; Feb. 16, 2011. This funding opportunity will use the R21 award mechanism. For more information see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3867. Inquiries: Dr. Young S. Kim - firstname.lastname@example.com. Correlative Studies with Specimens from Multisite Trials Application Receipt Dates: Non-AIDS Applications (new): June 16 and Oct. 16, 2008; Feb. 16, June 16, and Oct. 16, 2009; Feb. 16, June 16, and Oct. 16, 2010; Feb. 16, 2011. This is a renewal of PA-06-296 and will use the R21 award mechanism. For more information see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3868. Inquiries: Dr. Heng Xie - email@example.com. Exploratory/Developmental Grant for Complementary and Alternative Medicine Studies of Humans Application Receipt Dates: Non-AIDS Applications (new): June 16 and Oct. 16, 2008; Feb. 16, June 16, and Oct. 16, 2009; Feb. 16, June 16, and Oct. 16, 2010; Feb. 16, 2011. This is a renewal of PA-06-510 and will use the R21 award mechanism. For more information see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3869. Inquiries: Dr. Jeffrey White - email@example.com. |
Dr. Asad Umar, acting chief of the Gastrointestinal and Other Cancers Research Group in NCI's Division of Cancer Prevention, offers his insights into the implications of two major colorectal cancer chemoprevention studies presented at the 2008 AACR annual meeting. What is your reaction to the APC and DFMO/sulindac trial results? NCI's Division of Cancer Prevention funded the DFMO/sulindac study, and we were confident that this was a well-designed study. We now see that this is an excellent combination for preventing the recurrence of colorectal adenomas, particularly advanced adenomas, which have the highest risk of becoming cancer. The big question is always: How will the animal model results translate to human trials? In this case, the animal models predicted accurately. Nonsteroidal anti-inflammatory drugs like celecoxib and sulindac, and the ornithine decarboxylase inhibitor DFMO, have all shown efficacy as single agents, and there was a synergistic effect when they were given in combinations in animal chemoprevention studies. In the APC trial, the efficacy did drop after participants stopped taking the drug, but there was still a statistically significant reduction in adenomas after being off the drug for two years. And, importantly, the strongest effect was seen in advanced adenomas, the polyps most likely to progress into cancer. What are your thoughts about the cardiac affects related to celecoxib in the APC trial? The NCI-funded meta-safety analysis by Dr. [Scott D.] Solomon and colleagues, which includes the APC trial, provides a better understanding of celecoxib's safety profile. By pooling the safety data from six different trials, we can better assess the cardiovascular risk of celecoxib. We saw that this risk was greatest in those with pre-existing cardiac risk factors. In those patients without pre-existing risk factors at baseline, there was no significant risk of a cardiovascular adverse event, even with a high celecoxib dose. This result should be interpreted with some caution because the number of individuals in the low cardiac-risk category was small. However, this is an important finding because we can stratify patients according to their underlying cardiac risk factors in future studies. We now have two approaches that may effectively prevent colorectal cancer precursors. What are the next steps? There are a couple of things that we need to think about. How do we best design the next celecoxib trials to stratify populations into appropriate risk categories and minimize the risk of cardiovascular toxicity? We need to identify the population in which the benefits of polyp prevention will be greater than any potential risk of taking celecoxib. We also need to better define the lowest effective dose and dosing regimen. Participants in the PreSAP trial, who were given 400 mg of celecoxib once a day, experienced fewer instances of cardiovascular toxicity compared to patients who took 200 mg twice a day or 400 mg twice a day. We can design the next trial to evaluate a once-a-day regimen with a lower dose or an every-other-day regimen. We also might want to conduct additional animal studies to see if we can decrease toxicity and maintain efficacy for adenoma prevention with a "drug holiday" approach. As for DFMO/sulindac, Dr. [Frank] Meyskens and his colleagues are planning a larger trial of this combination. To get regulatory approval, we'll need to show that these drugs, as single agents, are effective. Future trials will need to include several treatment arms: sulindac alone, DFMO alone, and DFMO plus sulindac. We are also excited that, based on the results from these studies, other investigators are interested in studying the mechanisms of chemoprevention for nonsteroidal anti-inflammatory drugs and DFMO, and we have requests to test DFMO as a cancer prevention agent in other settings including skin cancer. These agents may well have applicability beyond colorectal cancer. |


text:
Welcome back,
The Universal Selection Source: Polymer Additives
A SpecialChem Client is seeking to remove solid fat such as triglycerides from fabric substrates such as cotton and polyester at temperatures below 25°C in a liquid environment.
Proprietary active packaging technology was developed for extending the shelf life of postharvest horticultural products. The technology can be incorporated into conventional packa...
A SpecialChem Client requires a technology that delivers an instant optical blurring effects on the skin, i.e. immediately reduces the appearance of fine lines, pores and blemishes...
A SpecialChem Client is seeking a thin film polymer barrier to spray coat into metal beverage and food cans at high speed. This polymer barrier must be resistant to mechanical bend...
This technology allows selective separation of metals from solid or liquid mixtures. Given the nature of this technology, it can be tailored to separate specific elements. Industri...
Next Course Hot Melts Optimization for Quality at Lower Costs Mar 10, 2015
More info and registration
Next Course US Patent Claims: Reading & Interpretation Made Easy Mar 11, 2015
Next Course Compatibilizers for Base Paint and Colorant: Optimal Selection and Use Mar 17, 2015
Biobased Solutions
Innovation on Flame Retardants
PVC and Sustainability
do you have any suggestions on how we can make our product selection better or more suited to your needs? Please let us know by filling in the form.
Do you know which reinforcement solution among glass fiber, glass bead and a fiber/bead blend best fit your need? Take a look at our infographic to know the difference between each solution and determine which one is the most suitable for you.


text:
Vegedus wrote:~Mat's Apartment~
Kenneth catched the notepad with a grin. "Way ahead of ya, man." he said, and tossed back a sealed, brown envelope. "It has all the details you need. Including a couple of passwords and such you need to gain entry. Has got the payment too."
"Really, thanks a lot, Mat." Kenneth said earnestly. "If nothing else, see it as a karmic balancer to all that other, well paid, nasty shit you do."
He went into a devious grin as he finally noticed the redhead. "And you get up to a lot of nasty shit, don't ya?"
Vegedus wrote:~Central~
The co-worker looked at Samuel and the phone with disbelief. He was not entirely sure if he really wanted a dangerous phone like that. A couple of the other workers there looked a bit concerned, but there was something else grabbing at Samuel's attention now. There had been an anomaly in the grid in a certain area, B-4:5, for a while. It was very small, looking very much like a regular power flux, but it was also terribly consistent in it's placement, moving about like something living. It could very well be surger, though the signature did not match any known ones.
NOX wrote:Captain's Log - 9/7/2009
Pandora's box was not filled with candy.
Users browsing this forum: No registered users and 4 guests


text:
About Us
Mercadito Hospitality has grown from its first New York City restaurant location in 2004 to become a renowned restaurant group. The popularity of the group's restaurants can be attributed to Partners Alfredo and Felipe Sandoval, innovative culinary interpretations created by Chef/Partner Patricio Sandoval, and its joint venture with renowned consultants Paul Tanguay and Tad Carducci – the Tippling Bros – who bring inimitable flavor profiles to the group's beverage programs.
Based in Chicago, the group owns and operates restaurants and bars across the U.S. including the flagship concept, Mercadito in Miami, Chicago, and New York City; Double A, a cocktail lounge located beneath Mercadito Chicago; Tavernita and Barcito in Chicago's River North neighborhood; and Mercadito Fish at Chicago's Talbott Hotel.
MH Catering was launched in 2013 and the group's newest concepts, Tippling Hall (Chicago) and Mercadito Counter (Chicago) will open late 2013. Additional projects in Las Vegas, Philadelphia are slated to open in 2014.


text:
Don't forget to check out the CarFinder request form if you can't find your ideal match. We can find it for you and let you know when we get it in stock!
* The advertised price does not include sales tax, vehicle registration fees, other fees required by law, finance charges and any documentation charges.
* Images, pricing and options shown are examples, only, and may not reflect exact vehicle color, trim, options, pricing or other specifications.


text:
24.04.2012 / Arts & Culture
Minimalist landscapes
Being able to look at familiar objects with new eyes is not something within everybody's reach. It takes talent, powers of observation and the ability to see the potential of what's just under our nose.
Which is exactly what Gavin Dunbar does with his camera. Gavin's images portray landscapes – well, mostly seascapes - devoid of the human presence and populated by simple, isolated objects: rocks, reef, lighthouses, trunks, wooden posts.
Captured by the lens with high-contrast black and white patterns and a very simple and geometric frame, the subjects stand out against a soft, blurry background and seem to be floating in space.
The result is a series of dream-like, soothing and almost supernatural images. A set of minimalist landscapes with a "Nordic" flavour to them that will have you considering the opportunity to throw a fresh look at your everyday reality.
Based in Edinburgh, Gavin Dunbar calls himself an amateur photographer.
Yet, already at a first glance, his photographs seem to have much more to say than those of quite a few so-called pros.


text:
Most Recent Articles In People
Latest People Articles
- FN Pick: Match Point
- Two Ten Toasts 75 Years
- FN Spy: Six Degrees of "Sex and the City"... Stan Stuns
More Articles By
Dreamed a Dream
Imagine a world without heels. The period drama, "Les Misérables," set in 19th-century France, is just that. "It was a very special period for shoes, it was very unique. The heels disappeared completely for women," said costume designer Paco Delgado, who used all custom footwear on set. And the specially crafted shoes came from a variety of global factory locations, including Rome, Madrid and London. Here, Delgado tells Spy about his trip back in time.
What was it like working with female lead Anne Hathaway?
"She's vegan, so we couldn't use any animal materials on the shoes for her character Fantine. We had to find very specific shoemakers to create lace-up boots and ankle boots. We also did flats that were much more sophisticated."
What about footwear picks for the men on set?
"Hugh Jackman [playing Jean Valjean] had a combat leather boot look and very rough espadrilles. He also wanted to wear wooden clogs. It was very difficult to walk in them, but he figured out how to do it. And for Russell Crowe [in the role of Javert] it was all boots."
Any memorable behind-the-scenes footwear moments?
"We were shooting the actors singing in real time, so [we were] very careful with the materials we used to be as noiseless as possible. We used soft materials and insoles to stop the noise."
Rock On
It's going to be a rockin' spring for Sebago. The Rockford, Mich.-based brand has joined creative forces with rock band Linkin Park for a limited-edition boot. According to Sebago GM Gary Malamet, the boot is the result of efforts by band DJ Joe Hahn, an admitted sneakerhead. "He put his inspiration into it," Malamet said about the handcrafted industrial-inspired style infused with Sebago's DNA. "We're genuine and the [band] is genuine." Scheduled for a 1,000-pair run, the co-branded boot will retail for $250. Delivery is slated for January, timed for the band to wear on its tour, which kicks off in California next month. According to Malamet, a portion of proceeds from the boot's sale will go to Music for Relief, a project launched by Linkin Park to aid natural disaster victims, including those impacted by Hurricane Sandy.
Life of the Party
Anastasia Ganias is already a fan of Jimmy Choo, but the "True Blood" actress also had another reason to shop the label's cruise '13 collection last week. Jimmy Choo teamed up with DKMS Delete Blood Cancer for a star-studded "Celebrate the Gift of Life" cocktail event to raise awareness and benefit the bone marrow donor center. "My father is a blood cancer survivor, so for me it was super-personal, and I think it's important to spread the word," said Ganias, a new member of the "True Blood" cast, who portrays fashion boutique owner Tracy Togs. Also quite the fashionista in real life, Ganias donned a pair of tan-and-black Jimmy Choo pumps for the occasion. "I'm a seasonal dresser," she noted. "As much as I love the open-toe [styles], I stand by that." Other labels in the actress' closet include Rag & Bone and Manolo Blahnik. "I am also a Prada junkie," she confessed. Other familiar faces spotted at the event were Jimmy Choo U.S. President Brian Henke, The Man Repeller's Leandra Medine, reality star Kelly Bensimon, model Tali Lennox and pop duo Karmin, who performed songs from their debut album "Hello."
Puppy Love
Anna Sui has Hush Puppies on her mind. Not only will she be collaborating with the comfort brand for a second season in fall '13 but she also plans to spend the holidays in their shared home state. "I'm going back to Michigan, where Anna Sui and Hush Puppies are from," the designer quipped. While she was tight-lipped about the look of the next collection, Sui added that her recent fashion inspirations have come from a bygone era: "There's a whole 1960s thing going on, and I find that really exciting."
Flower Power
Toms Shoes is getting romantic just in time for Valentine's Day. The brand partnered with homewares label Shabby Chic for two styles — one wedge and one flat — featuring floral prints fit for the holiday. "[Shabby Chic] holds a special place in the hearts of women and girls everywhere," said Toms founder Blake Mycoskie. "We love how their iconic floral prints add a sophisticated touch to our classic slip-on and wedge silhouettes." Retailing for $59 and $74, the styles will sell at Rachel Ashwell Shabby Chic Couture stores and at Toms.com starting in February. In the spirit of Toms' charitable mission, Shabby Chic will donate a portion of proceeds to Upward Bound House, a nonprofit focused on homeless families.
Shoeing Shay
Two shoe closets are certainly better than one. Actress Shay Mitchell, who is gearing up for the second half of season three of ABC Family's "Pretty Little Liars," starting in January, said she's also looking forward to raiding the stash of her character, Emily Fields. "A lot of the boots are really great. I love them and I am always taking them from Emily's closet," said Mitchell. "She's more casual [than the other characters], but she is dressing up her style a lot more now, and it's a lot of fun." So what are Mitchell's most coveted pairs? "[Emily] has a lot of AllSaints boots that I love, and Steve Madden is amazing."
Sasha's Sole
Fans of figure-skating champ Sasha Cohen can finally see what it's like to be in her shoes. Cohen has teamed up with Klingbeil USA (a line of ice and roller skates owned by The Adoni Group Inc.) to design a skate style for the mass market, and each pair will be embossed with Cohen's signature. "Amazon.com has put in a huge order," she told Spy at a recent party held at the brand's Manhattan factory. "We are launching in January, and we have a photo shoot next week, so it's really exciting. [The ice skates retail for] around $80 to $90, including blades, so it's really affordable." Off the rink, Cohen says she prefers comfy flats, with one exception: "I'm only 5'1," so when I go out I wear heels. But this is New York — it's hard to find something you can walk 30 blocks and then dance all night in."


text:
Last Modified: July 8, 2010
Dear OncoLink "Ask The Experts,"
My friend told me I was at a greater risk to get osteoporosis because I had cancer, is this true? If so, what should I do about it?
Christine Hill-Kayser, MD, Assistant Chief Resident in the Department of Radiation Oncology at the Hospital of the University of Pennsylvania, responds:
Risk of osteoporosis can be a real problem after completion of cancer treatment. This risk is highest and most common for breast cancer patients who are treated with aromatase inhibitors, such as arimidex. If you are receiving treatment with an aromatase inhibitor, bone density scan (dexa-scan) should be performed yearly during treatment, and treatment for bone density may be indicated. Other patients who may be at risk for osteoporosis are men who are receiving hormonal treatment after prostate cancer. Any post-menopausal woman should have a bone density evaluation at least every 5 years, regardless of specific treatments. Effective treatments for osteoporosis do exist, and screening can allow your doctor to help you receive these treatments if they are indicated. This article on bone health after cancer may be helpful.
This question and answer was part of the OncoLink Brown Bag Chat Series, Cancer Survivorship Webchat. View the entire transcript on survivorship.
Feb 15, 2010 - Using magnetic resonance imaging in addition to the usual triple assessment for breast cancer diagnosis does not reduce the risk of repeat operation and is not a good use of resources, according to a study published in the Feb. 13 issue of The Lancet.


text:
Moderator: LGB Mods
cardsfan04 wrote:I couldn't sit through the 9th. I was pacing around my living room.
cardsfan04 wrote:Relief is a good word for it. I can take losing game 5, but if McCutcheon would have hit a 2R HR, that would have been too much.
Now, with the Dodgers winning, game 5 is at the same time as Blues/Blackhawks.
Return to Everything Else [OT]
Users browsing this forum: No registered users and 3 guests


text:
quote:i thought you were a gump i guess you support both of the axes of evil
quote:What the heck happened to this thread?
quote:I still think Peter needing his tech removed
quote:Walter wanting his bad brain parts removed...is going to be an issue going forward.
quote:In season 3 there was a man who had "advanced so far he could see the past, present, and future" .. when they attempted to stop him, and keep him from being able to do this, he tried to have everyone killed, Olivia, not being from the Redverse did not understand the signals like the other people in the Redverse and survived the attack - and stopped the guy.
quote:What ep was this? Vaguely ringing a bell...
quote:Ringing a Bell
quote:Is Bell gonna take over Olive's body again?
quote:I'm still waiting for Agnes to have a significant role in this whole deal...wonder what that could be?
quote:agnes is going to be the one to keep walter from going full old walter.
quote:agnes is going to be the one to keep walter from going full old walter. As long as it involves the laser, I'm down.
quote:no no, the grape licorice is going to be the key to it all.. duh
quote:I really hope they don't skip over this detail.
quote:You do know John Nobel has already said there is a reason for it.. right?
quote:i dont want to hijack the bbt thread anymore so i will respond to you in this one. i would NEVER move to gump land!!!!!!!!!!!!!!


text:
Baby Toys > Baby Play Mats
Keep infants in a safe environment withour collection of soft and colorful baby mats. Kaplan Toys offers bouncers, activity gyms, cushions, and mats for children who enjoy lying on their tummies.
Tummy Time Fun Frog Pillow & Mat Tiny Love Price: $32.95 In Stock Crawl & Discover Mat Manhattan Group Price: $49.95 In Stock Baby Einstein Rhythm of the Reef Play Gym Kids II Price: $71.95 In Stock Boppy® Pillow with Backyard Blooms Slipcover The Boppy Company Price: $40.95 In Stock Bestever Pink Owl Baby Mat Mary Meyer Corporation Price: $49.95 In Stock Grow-With-Me Activity Gym & Ball Pit Infantino Price: $71.95 In Stock My Little Lamb Infant Seat by Fisher Price Fisher Price Toys Price: $89.95 Sale Price: $69.95 In Stock Bestever Frog Baby Mat Mary Meyer Corporation Price: $49.95 In Stock Play Gym - Flying Circus with Toy Box The Boppy Company Price: $71.95 In Stock Boppy® Waterproof Liners (Pack of 3) The Boppy Company Price: $13.95 In Stock Cuddle-U® Leachco Price: $34.95 In Stock LuLu the Turtle Price: $169.95 In Stock Treetop Friends Activity Gym Skip Hop Price: $79.95 In Stock Luv U Zoo™ Musical Mobile Gym Fisher Price Toys Price: $77.95 In Stock Kick & Crawl Gym Fisher Price Toys Price: $45.95 In Stock Soft Mat Edushape Ltd Price: $56.95 In Stock


text:
Donate | Español
Nursing Continuing Education Modules Free continuing education activities designed for nurses and nurse practitioners in clinical practice.
Self-Care Series for Oncology Professionals This continuing education activity is designed to enable the learner to understand the challenges of working in oncology and how they can maintain a healthy work-life balance.
CME-certified Oncology Medical Minutes Continuing medical education (CME) programs, delivered by world-renowned experts in their fields, sponsored by QuantiaMD.
MD2B: Hematologic Malignancies
MD2B: Introduction To Oncology
MD2B: Pediatric Cancers
Feb 20, 2013 - A universal screening approach for all newly diagnosed colorectal cancer patients improves identification of Lynch syndrome, according to a study published online Feb. 11 in the Journal of Clinical Oncology.
Feb 20, 2013
Oct 18, 2012
Jan 3, 2014
View More News
Select the side effects and forms for your patient's treatment binder
Learn More
View More
Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!


text:
LG Light Bulbs
LG Electronics has been producing high-quality goods since 1958. The company is constantly developing, bringing customers to an advanced digital epoch. LG items are stylish but simple. LED light bulbs are energy-saving, meeting all the needs: illuminating and decorative as well. Buy products by LG and explore their perfect design and high efficiency. They are sure to suit any space in the house.
Types of LG Light Bulbs
LG Electronics offers the succeeding types of bulbs:
A 19: No difficulty when installing. These lamps economize up to 80 % of the electric bill in comparison with standard incandescents. Moreover, they are long lasting. A 19 items are perfectly suitable to bedrooms, bathrooms and kitchens, front doors. Color temperature varies from 2700 to 3000. 12.5W bulbs are appropriate to dimmer lamps.
Candle: Providing any place with a classical atmosphere. They create distinctive and brilliant light, make the interior more stylish. The life time is about 20,000 hours. LG Candle Light Bulbs are easy to install and replace. The items are certain to save the users' cash thanks to long-term durability.
MR: An ideal variant for accent lighting. These bulbs are rather practical, saving money and energy. The company uses no mercury when producing the bulbs. Besides, no ultraviolet or infra-red rays are emitted. One more peculiarity is a broad compatibility. Bright and distinctive light given by MR helps to emphasize any decorative elements or special objects in the room. Due to reduced flickering MR bulbs are healthier to eyes, not causing eye fatigue. The items are perfectly suitable for using in public places (shops, cafes, hotels) as well.
PAR: Making your room clearer, brighter and more distinct. PAR bulbs by LG may be used for decorative and functional purposes. They add a cozy spirit to the interior. Hotels, shops, public places, even corridors and stairways are locations for these bulbs. The rating life is about 25,000 hours. PAR30 Lamps are 13W (replacing 60W or 75W), PAR38 Lamps are 16W (replacing 75W or 90W).
Retrofit Downlight: Possessing dimming control. This kind of illumination is cost-effective, saving money and users' efforts (35,000 hours of work allow not replacing bulbs for more than 10 years). Retrofit Downlight may be applied in houses, department stores, commercial and office areas.
Buy LG Bulbs and enjoy high-rate lighting.
LG LED Light Bulb, A19 Standard Edison Base10 120V, 12.5W (60 Watt Equivalent) - Dimmable - 2700K - 810 Lumens
How to Select
How to select Light Bulbs
Light bulbs are the most essential parts of any lighting fixture that is why you need to pay additional attention when selecting them. The following guide will help you make the best choice among hundreds of options that exist today.
The first choice that you need to make is the lighting technology used for light bulb creation. Here are the most common types that exist today:
- Fluorescent bulbs. Such type efficient and long-lasting and is traditionally used with residential and commercial ceiling fixtures.
- CFL bulbs. This is the type of compact fluorescent lamps that use a mixture of gases to illuminate the area. Such bulbs are able to retain their heat and thus light when heated, this is why they provide more light while using the same amount of energy.
- Incandescent Bulbs. Incandescent bulbs are the oldest and least efficient type of light bulb that is still commonly used because of its low and affordable price. Such light bulbs spend 30-40% more energy than fluorescent and in addition to that have a shorter life.
- LED bulbs. Are the most efficient, reliable and long-lasting bulbs that exist today. The LED technology emits light while electrical charge passes through the bulb. The scope of LED bulbs is wider than you think; they are used in most of the residential, commercial and even industrial light fixtures.
- Halogen bulbs. This type of bulb is the closest you will ever get to sun light. It offers a natural colored light that is very similar the one produced by sun. Such light bulbs are mostly used for decoration purposes.
After the type of your future light bulb is specified, you need to consider its shape. The shapes that are present at today's market include a-line, spiral, globe, candle, tube, bullet and other. Each shape has benefits and fits particular light fixtures and installations.
Bulb base should also be considered before you buy the item. The best way to know if the base is compatible with the lamp or the fixture is to look for specifications of such device and compare them with the bulb's description.
Wattage and color temperature of a light bulb should also be considered. Knowing the wattage of each bulb installed in each fixture will help you plan your budget and, surprisingly enough spend less money and energy. Color temperature or the light's color only depends on your personal preferences. It is possible to find bulbs of every type with warm or cool colors; you only need to look for such information in the light's description.


text:
quote:And you would never talk shite to my face, Little Man.
quote:Strong recruiting class.. But like all the other years, no big names at the end. Happy with what we got, got a bunch of future pro bowlers
quote:Kragthorpe is leaving the staff, Stud is going back to OL, and Cam Cameron is our OC.
quote:Probably sarcasm but kragthorpe aint leaving the team while his son is on it
quote:lol, can't wait till I bump this in a few weeks...


text:
the knob wrote:Mellanby_equals_grit wrote:Furthermore, this is just an embarassing and pointless trade.. Brewer is an RFA and my guess is he'll command at least 2 mill a year. So if we say he gets 2.5 mill.. With the pro contracts for the other 2.. That's 3.5 mill a year.. Versus Pronger's 7.2 million. We're saving 3.7 (franking) million dollars.
This franchise is going to give away the best player that has ever put on its jersey (save Gretzky) so Bill Laurie can save 3.7 million? Are you f*cking kidding me?
Lynch won't be counting against the Blues' cap.
Woywitka is ready to start in the NHL.


text:
Dorks like Mouth are in! It's no wonder why popular girls Brooke and Rachel have a soft spot for this sports announcer. Like Mouth, it might take you longer to find The One (doesn't the "just friends" line stink?). But once you meet each other, you won't wanna let go -- you're both fun, loyal, and popular! Snag One Tree Hill: The Complete Fourth Season December 18 for a date with Mouth now.
Login to save this result
Don't have an account?


text:
Kusmi Morning Tea No. 24 - 20 sachets
Country of Origin: France
Region: Île de France
City / Village: Paris
This box contains 20 muslin sachets of Kusmi's Russian Morning N°24 (Thé du Matin) is a blend of three classic orthodox teas: a delicately-flavored Chinese black tea, a Ceylon black tea with lightly-twisted leaves and subtle chocolate flavor, and a full-flavored, malty, black tea from India.
The blend of these three naturally enticing teas makes a well balanced tea ideal in the morning. Steep for 3-4 minutes.
To learn more about tea, visit our tea education section.
Produced By: Kusmi
View All Products from Kusmi
Kusmi Morning Tea No. 24 - 20 sachets Product ID: 02993 |
Price | Qty |
$15.95 x | |


text:
quote:Good stuff. Will be cheering him on for sure.
quote:Could tell he was a genuine guy from the interview. Sounded nervous. Which I liked. Good to see a guy actually be a little nervous compared to most tour players that spout off some rehearsed answer.
quote:I could tell he was fighting back tears. Made me like him more.
quote:. It aggravated me to know end, so I know he couldn't stand it


text:
Product Number: | ZMM1AA1 |
Item Price: | $23.19 $17.99 |
Availability: | In Stock |
Shipping Weight: | 0.57 lb. |
A .308 Win. / 7.62x51mm, 20-rd Magazine for Springfield Armory M1A and M14 rifles. The magazine body and follower constructed of heat-treated steel with a parkerized finish for durability and harsh use in the field. A heat-treated Chrome-silicon wire spring ensures reliable feeding and function.
Customers who bought this item also purchased
Similar items: Pistol Magazines
Sort By:


text:
1G Daar El Defaa El Gawy Street Taaseem Asmaa Fahmy, off Nozha Street, Heliopolis Cairo . Egypt (T) +20 (0)2 2414 9310(F) +20 (0)2 2290 5989
TNS advises clients on specific growth strategies around new market entry, innovation, brand switching and stakeholder management, based on long-established expertise and market-leading solutions. With a presence in over 80 countries, TNS has more conversations with the world's consumers than anyone else and understands individual human behaviours and attitudes across every cultural, economic and political region of the world.
Data investment management
Consumer insight
Advertising and brand trackingBrand developmentConcept testingCopy testingCustomer satisfactionIdea generationMarketing analyticsMarketing effectivenessMystery shoppingPolitical and socialPositioning researchQualitative researchSegmentation researchStakeholder and employee research


text:
Community briefs
Thursday, January 17, 2013
Committee on Aging to meet Jan. 22
Each month the group hosts a meeting with topics related to health and/or living with Parkinson's disease. There is also a time for questions and sharing of information/experiences. These monthly meetings are open to anyone - individuals with Parkinson's disease, family members, partners, friends and caregivers. There will be a facilitator present for this month's meeting. For more information, contact Claire Moorhead at (603) 254-5583 or email@example.com.
Attention schools that are served by End 68 Hours of Hunger: each school will win a pizza party for the class that brings in the most donations. Any family who brings in more than 50 items will be entered in a drawing for a birthday party for 10.
Caroline French is the vice-chair of the Dover Democratic Committee; Bill Dudley, secretary, and Carole Appel, treasurer. |


text:
CBU Advancement
At California Baptist University, we believe every student was created for a purpose. Our graduates are challenged to become individuals whose skills, integrity and sense of purpose glorify God and distinguish them in the workplace and in the world.
We are thankful for the generous private support of our alumni, parents, and friends, whose gifts provide students with an educational experience that will equip them to become effective local and global Christian leaders. Whether you choose to give to scholarships or academic programs, your support is critical to continuing the CBU tradition of providing a Christ-centered education.
CBU Fund
Gifts to the CBU Fund help to support the current initiatives, priorities, and areas of greatest need at the university. From scholarships, laboratory equipment, library resources, research technology to academic program development, your gift will have a profound impact on the lives of students today and in the years to come.
Lancer Athletics
On behalf of California Baptist University, Lancer Athletics, our coaches and more than 400 student-athletes, thank you for your interest in the Lancer Athletics Association (LAA). Whether you are a long-time supporter or first-time donor, I want to emphasize the importance of your decision to contribute to the LAA. Every dollar donated directly impacts CBU Athletics' ongoing mission of academic, athletics and spiritual success. We are excited about the opportunities opening up to us with a move to NCAA Division II, and welcome this new chapter in CBU Athletics. With your partnership, we will continue to build upon our 22 NAIA and 8 NCCAA National Championship and ensure that our student-athletes have the resources necessary to succeed beyond their collegiate experience.
Board of Visitors
Since 2001, the Board of Visitors at California Baptist University has been comprised of influential business and community leaders whose professional interests represent the distinct departments and programs of the University.
Women of Vision
Women of Vision at California Baptist University is a group of women who have an affinity for CBU. The group and its activities are designed to educate women on the true joy of giving, the importance of philanthropy, and to encourage them to act on their desire to give.


text:
Main Content
You leave nothing to chance when it comes to the Orioles. As their number one fanatic, you know that every bit of good juju is important! You'll be good to go when you gear up for game day starting with these Prospect panties! These cotton panties feature an allover Orioles print that includes several O's-themed logos and the edges have a micro-scalloped trim for a girly bonus! With these panties you'll be able to relax, knowing that you've taken your Baltimore fanaticism to a whole new level of awesome!
- 100% Cotton
- Bow applique on front
- Imported
- Micro-scalloped trim
- Officially licensed MLB product
- Sublimated graphics
Special event items are produced by manufacturers only after the outcome of a game
or event. These are advanced sale items and will ship immediately after they are
received in our warehouse.
Manufacturer direct items are shipped directly from the manufacturer. These items
are not available for international or expedited shipping.
Customized items can be personalized with options such as your name, your favorite
number, and/or designs. Some options may be limited by league rules.


text:
0 Members and 1 Guest are viewing this topic.
OMG!....I saw "Rose's" and thought, for a bad flash moment, our jeff had gone bad. Don't ever do that again dude.
Were you thinking Wild Irish Rose? Things aren't that bad...
Just finished my 3rd cup of Chic-fil-a coffee.
Now head out on a three hour drive and fun filled game of man versus bladder.
I enjoy a Becks once in awhile. Those pics look very "alive" and pretty Norma. Are they from your new camera? Really nice.
Yeah, that's what I thought might have happened. If you look at the colors of things at the stall owner across from you they look exaggerated, brighter. Those little cameras today are really neat, like you said, they can do a lot of stuff. Bob
Bob,You're not by any chance on acid right now are you?The only reason I ask is because I just ate some psychedelic mushrooms ad I noticed the same thing!!! Cool pics Norma! They should hire you at Linenkuegel's (and Beck's!!) to do their artwork!John K
Cool pics Norma! They should hire you at Linenkuegel's (and Beck's!!) to do their artwork!John K


text:
Computed Tomography Angiography
- Home
- Health Information
- Computed Tomography Angiography
- Brain
- Heart
- Lungs
- Kidneys
- Legs or arms
Blood Vessel in Brain |
Copyright © Nucleus Medical Media, Inc. |
Reasons for Test
- Detecting atherosclerosis , a narrowing of the arteries
- Detecting an aneurysm, a ballooning out of a section of a blood vessel
- Examining arteries in the lungs to check for blockage of a blood vessel
- Evaluating disease in kidney arteries
Heart Attack |
Copyright © Nucleus Medical Media, Inc. |
Possible Complications
- Allergic reactions to contrast material
- Excess bleeding
- Kidney damage
What to Expect
Prior to Test
- You will remove your clothes and put on a gown or robe.
- You will remove all jewelry, hair clips, dentures, and other objects that could show on the x-rays and make the images hard to read.
Description of Test
After Test
How Long Will It Take?
Will It Hurt?
Call Your Doctor
- Signs of allergic reaction, including flushing, hives , and itching
- Swollen or itchy eyes
- Difficulty breathing or a feeling of tightness in your throat
- Nausea
American Heart Association http://heart.org
Texas Heart Institute http://texasheartinstitute.org
Heart and Stroke Foundation of Canada http://heartandstroke.ca
University of Ottawa Heart Institute http://ottawaheart.ca
Cardiac computed tomography. American Heart Association website. Available at: http://www.heart.org/HEARTORG/Conditions/HeartAttack/SymptomsDiagnosisofHeartAttack/Cardiac-Computed-Tomography-Multidetector-CT-or-MDCT%5FUCM%5F446370%5FArticle.jsp. Updated November 6, 2012. Accessed May 6, 2013.
Coronary computed tomography angiography (CTA). Radiological Society of North America Radiology info website. Available at: http://www.radiologyinfo.org/en/info.cfm?pg=angiocoroct. Updated April 22, 2013. Accessed May 6, 2013.
Revision Information
- Reviewer: Michael J. Fucci, DO
- Review Date: 03/2014 -
- Update Date: 05/02/2014 -


text:
Assistant Professor
Old Main
Campus Mailbox: 94
(724) 946-7185
About Me
Dr. Sararose Lynch is an Assistant Professor in the Education Department. She received her Doctoral degree from West Virginia University in Curriculum and Instruction with an emphasis on Mathematics Education. Her undergraduate work focused on Secondary Mathematics Education at West Virginia Wesleyan College and her Masters degree is in Rehabilitation Counseling with an emphasis on secondary and post-secondary aged students with disabilities from West Virginia University. Prior to moving to Pennsylvania, Dr. Lynch was a middle school mathematics and special education teacher in West Virginia. She also taught special education and was a transition counselor for high school students with disabilities in Maryland. Her research interests focus on classroom mathematical discourse, pre-service mathematics teacher preparation, and mathematics instruction for students with disabilities. Dr. Lynch is involved with the National Council of Teachers of Mathematics, the Association of Mathematics Teacher Educators, and the Council for Exceptional Children and has presented papers at several national conferences.


text:
Following David Beckham's announcement to leave the MLS, football (or soccer) fans around the world have been speculating as to where his next stop will be. Currently seven clubs (Real Madrid, AC Milan, QPR, Shanghai Shenua, Monaco, PSG, and Manchester United) have been rumored to have an interest in Beckham. At thirty-seven years of age, Becks isn't what he used to be, so choosing a team and league will take a lot of serious thought, or will it? Sega's Football Manager did a simulation where they placed Beckham in each of the seven rumored teams he's rumored to be joining in January.
Beckham at Monaco
Monaco is currently in France's Ligue 2 division. Beckham would undoubtedly be the best player in the club. He averages 7.89 in 17 appearances and creates 11 assists for his team-mates, easily bringing Monaco the Ligue 2 title. Once ascending to Ligue 1, Beckham would remain a key player. Though they wouldn't win the cup, they'd finish with the 10th spot, averaging a rating of 7.58 across 27 appearances. By the end of the simulation, Beckham became a fan favorite at the club.
Beckham at QPR
QPR Head coach Harry Redknapp has said he'd like Beckham to lead QPR out of the bottom of the standings of the Premier League. During Redknapp's time as head coach of Tottenham Hotspur, he attempted to get Becks on loan transfer from the LA Galaxy. In the simulation, Beckham helps QPR remain in the Premier League, averaging a rating of 7.38. Redknapp changes his formation in the second season to a diamond 4-4-2, making Beckham useless and giving him very few minutes on the pitch. By the end of the simulation, Beckham is unhappy at QPR and wants out of the team.
Beckham at A.C. Milan
Returning back to the diavoli (the devils) would take some pressure off head coach Massimilliano Allegri since over the past 12 months, Milan have sold a lot of their key players. In the simulation, Allegri signs Beckham in January, but the midfielder isn't a big part of his plans. After only 6 appearances with AC Milan, Beckham is dropped down to the reserve squad. Beckham would remain in the reserves for 6 months of the 2013/14 season before announcing his retirement.
Beckham at PSG
PSG is a regular at the Champions League. Regardless of their success they don't seem to have the strong fan base they deserve, a big name like Beckham could help change this. Beckham would put PSG on the global spotlight. However PSG head coach, Carlo Ancelotti might find it hard to find add Beckham to his already talented squad. Beckham finds his way to the first-team until the end of the 2012/13 season. The team wins the Ligue 1 title with impressive performances from Beckham against top teams like Bordeaux, Lyon, and Marseille. His second season is less as exciting for Becks as he loses his right midfield position to Jeremy Menez and Ezequiel Lavezzi who are both currently at the club. Beckham only makes 5 appearances in his second season and no longer serves a purpose at the club.
Beckham at Shanghai Shenhua
In recent years, Chinese soccer has shown improvement though out the league. Shanghai Shenhua already is already home to Didier Drogba and Nicolas Anelka. Adding Beckham to the squad would not only help the squad, but the league because of the star power and quality of players. In the simulation, Beckham brings in higher attendances and higher jersey sales to the Chinese Super League. Unfortunately for Shenhua, they have a disappointing season and finish in 9th place. Only Beckham and Drogba would perform above average. Beckham provides a spectacular 17 assists in his debut season, earning him 11 Player of the Match awards. By the end of the simulation, Beckham is still playing regular first-team football, something he hasn't done at any of the other clubs. Unfortunately for Beckham, his season is cut short due to an injury.
Beckham at Manchester United
A return to where it all started is still an option for David Beckham. Sir Alex Ferguson still uses his veteran stars Ryan Giggs and Paul Scholes (which have played at United their entire careers), so Beckham wouldn't look out of place. Beckham would make a handful of appearances at Old Trafford, but for the most season he'd serve as a backup to Nani. In games he would play, he'd score an average of 6.83 goals. Manchester United would finish at second place in the Premier League, behind their fierce cross-town rivals Manchester City FC. Beckham would play in the crucial Manchester derby on April 6th, but would face disappointment as City wins 3-1. In the 2013/14 season, Beckham is no longer in the plans of Sir Alex Ferguson and announces his retirement in February.
Beckham at Real Madrid
Real Madrid isn't shy from hiring the biggest names in football-soccer. Real Madrid's president, Florentino Perez is obsessed would love the chance to bring Beckham back to Madrid. Head coach Jose Mourinho also wouldn't mind as he's stated that he admires David Beckham's quality of play. The simulation highlighted the main issues that Beckham would face. Madrid's squad is already packed with talent. Beckham would have to earn his place against players like Cristiano Ronaldo, Kaka, Luke Modric, and Xabi Alonso. With only three appearances, it becomes clear that Beckham is no longer at the level Real Madrid expects their players to be.
By the look of it, Football Manager's simulations show that Monaco would be the best fit for Beckham. Monaco is the only club where Beckham could most likely finish his career off with one final league title. Football Manager recently simulated the MLS Cup final where-days before the match-they predicted LA Galaxy as the MLS champions.
Leave your comments below and add to this discussion. Like what you saw, follow us on Twitter @GamerFitNation, like us on Facebook and follow us on Google+ GamerFitNation!


text:
quote:Nah I did just fine taking Rodgers 1 this past year, and the year before taking him 4
quote:I see you've changed your tune regarding Lesean McCoy. At the end of the day, Bryce Brown is still just Bryce Brown.
quote: I'd rather grab the #10 and #11 QBs and take my chances.
quote:Fitzgerald with Andy Reid and a new QB will be money.


text:
This site uses cookies and similar technologies to customize and enhance your online experience. By using this site, you accept our use of these technologies. To learn more, please read our cookie policy.
Download the 2013-14 Detroit Pistons Schedule
Download the 2013-14 Detroit Pistons Schedule
Keep your schedule up to date with the Detroit Pistons as they embark on a brand new season. You can now download the 2013-14 Detroit Pistons regular season schedule.
Steps to Add to Microsoft Outlook:
1. Save the file available at the following link: http://www.nba.com/pistons/schedule/2013/schedule.ics
2. In Outlook 2010 Click on the File Tab -> Open -> Import | In Outlook 2007 Click on the File Menu then click on Import and Export
3. Highlight "Import an iCalendar (.ics) or vCalendar file (.vcs)" then click Next
4. Choose the location where the iCalendar (.ics) file is saved and Click on Ok.
5. Once the file is chosen the data will import to Open as New or Import
6. When the Open as New is chosen the file will open as a separate Calendar beside the Personal Exchange Calendar. Click the Import to actually import the data to your calendar.
Alternate Outlook 2010 instructions:
1. From Outlook, select 'Open Calendar > From Internet'.
2. Copy and paste http://www.nba.com/pistons/schedule/2013/schedule.ics in the 'New Internet Calendar Subscription' field.
3. Click 'OK'.
Steps to Add to your Google Calendar:
1. In the Other Calendars section at the bottom of the calendar list on the left, click the 'Add' button and select 'Add by URL'.
2. Copy and paste http://www.nba.com/pistons/schedule/2013/schedule.ics in the 'Public Calendar Address' field.
3. Click 'Add'.
Steps to Add to your iCal for MAC OS users:
1. Choose File > New Calendar Subscription in iCal.
2. Copy and paste http://www.nba.com/pistons/schedule/2013/schedule.ics in the 'Subscribe To' field.
3. Click 'OK'.
*Please note: Game times are subject to change.